Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - - Cialis Attains Leading ED Market Share Position in Eleven Countries - - 2006 First Quarter Net Income Soars to US$65.0 Million, Compared to Net Loss of US$41.7 Million in Prior Year Quarter - Lilly ICOS LLC (Lilly ICOS) (NYSE: LLY and Nasdaq: ICOS) is releasing its financial results for the 2006 first quarter, ended March 31. Worldwide ...
Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - - 2005 Fourth Quarter Net Income Surges to US$61.4 Million - 2005 Worldwide Sales Grow 35% - Company Provides Update on Clinical Plan for BPH Lilly ICOS LLC (Lilly ICOS) (NYSE: LLY and Nasdaq: ICOS) is releasing its financial results for the fourth quarter and year ended December 31, 2005. For the 2005 ...
Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - Lilly ICOS LLC (Lilly ICOS) (NYSE: LLY and Nasdaq: ICOS) is releasing its financial results for the third quarter ended September 30, 2005, proudly reporting net income of US$19.8 million, compared to a net loss of US$21.4 million in the 2004 third quarter. Worldwide sales of Cialis(R) (tadalafil)(1) in the third quarter of 2005 totaled US$195.1 million, ...
Bothell, Washington and Indianapolis (ots/PRNewswire) - - Latest figures confirm success of Cialis in the global ED marketplace Lilly ICOS LLC (NYSE: LLY and Nasdaq: ICOS), marketer of tadalafil(1), a PDE5 inhibitor indicated for the treatment of erectile dysfunction (ED), announced today that the drug has achieved US$1 billion in global sales since ...
Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - Lilly ICOS LLC (NYSE: LLY and Nasdaq: ICOS), marketer of Cialis(R) (tadalafil), a PDE5 inhibitor indicated for the treatment of erectile dysfunction (ED), is pleased with the European Patent Office's (EPO) final decision to affirm its earlier ...
Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - - 2004 Worldwide Sales of Cialis Top US$550 Million - Lilly ICOS LLC (Lilly ICOS) (NYSE: LLY and Nasdaq: ICOS) is releasing its financial results for the fourth quarter and year ended December 31, 2004. Largely driven by the first year of sales in the United States, worldwide sales of Cialis(R) (tadalafil) surged 172% in 2004, to US$552 million, ...
London (ots/PRNewswire) - - Spontaneity and Self-Confidence Cited as Reasons Why Men Preferred Cialis In Second Study A recent analysis demonstrated that 80 percent of men who took 20 mg Cialis(R)(1) (tadalafil) for the treatment of erectile dysfunction (ED) and had successful intercourse reported ...
London (ots/PRNewswire) - - Patients with moderate-to-severe ED and comorbid conditions respond to Cialis Cialis(R)(1) (tadalafil) may effectively treat erectile dysfunction (ED) in men with a variety of comorbidities that can make the condition more difficult to manage, according to new studies released ...
Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - - Third Quarter 2004 U.S. sales of Cialis exceed US$70 million - Lilly ICOS LLC (Lilly ICOS) (NYSE: LLY and Nasdaq: ICOS) is releasing its financial results for the three and nine months ended September 30, 2004. Worldwide sales of Cialis(R) (tadalafil) in the third quarter of 2004 were ...
Buenos Aires, Argentina (ots/PRNewswire) - -- Additional Analysis Shows Couples Agree Cialis Improves Erectile Function in Men with ED and Increases Satisfaction with Sexual Experience -- An international study conducted in 21 countries showed that 82 percent of men with ED who were treated with 20 mg ...